Phase II Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatin/Paclitaxel with or without Daily Subcutaneous Amifostine in Patients with Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Seminars in Oncology

Volumn 30, Issue 6 SUPPL. 18, 2003, Pages 84-88

  Haddad, Robert ^a,b   Wirth, Lori ^a   Costello, Rosemary ^a   Weeks, Linda ^a   Posner, Marshall ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTIHISTAMINIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; GLUTAMINE; KERATINOCYTE GROWTH FACTOR; PACLITAXEL; PLATINUM DERIVATIVE; RADIOSENSITIZING AGENT;

ADVANCED CANCER; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG DOSE REGIMEN; DYSPHAGIA; ESOPHAGUS STENOSIS; FEEDING APPARATUS; FEVER; FRACTIONATION; GASTROSTOMY; HEAD AND NECK CANCER; HOT FLUSH; HUMAN; HYPOTENSION; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; RIGOR; SALIVATION; SIDE EFFECT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

EID: 1642435541     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.11.011     Document Type: Conference Paper

References (21)

1. Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. New Engl J Med 324:1685-1689, 1991
2. Vokes EE, Stenson K, Rosen FR, et al: Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: Curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 21:320-326, 2003
3. Machtay M, Rosenthal DI, Hershock D, et al: Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: A University of Pennsylvania phase II trial. J Clin Oncol 20:3964-3971, 2002
4. Haddad R, Norris C, Sullivan C, et al: Docetaxel, cisplatin and 5-fluorouracil based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: The Dana-Farber Cancer Institute experience. Cancer 97:412-418, 2003
5. Forastiere AA, Berkey B, Maor M, et al: Phase III trial to preserve the larynx: Induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, Intergroup Trial R91-11. Proc Am Soc Clin Oncol 20:2a, 2001 (abstr 4)
6. Haddad R, Tishler RB, Norris CM, et al: TPF-based induction chemotherapy for head and neck cancer and the case for sequential, combined modality treatment. Oncologist 8:35-44, 2003
7. Pignon J, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell cancer: Three meta-analyses of updated individual data. Lancet 355:949-955, 2000
8. Fu K, Pajak T, Trotti A, et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7-16, 2000
9. Rose-Ped AM, Bellm LA, Epstein JB, et al: Complications of radiation therapy for head and neck cancers. The patient's perspective. Cancer Nurs 25:461-467; quiz 468-469, 2002
10. Trotti A: Toxicity in head and neck cancer: A review of trends and issues. Int J Radiat Oncol Biol Phys 47:1-12, 2000
11. Harrison LB, Zelefsky MJ, Pfister DG, et al: Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck 19:169-175, 1997
12. Jensen AB, Hansen O, Jorgensen K, et al: Influence of late side-effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer. Acta Oncol 33:487-491, 1994
13. Balogh JM, Sutherland SE: Osteoradionecrosis of the mandible: A review. J Otolaryngol 18:245-250, 1989
14. Korsten MA, Rosman AS, Fishbein S, et al: Chronic xerostomia increases esophageal acid exposure and is associated with esophageal injury. Am J Med 90:701-706, 1991
15. Staar S, Rudat V, Stuetzer H, et al: Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - Results of a multicentric randomized German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 50:1161-1171, 2001
16. Brizel D, Wasserman T, Henke M, et al: A phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345, 2000
17. Sutharalingum M, Haas M, Conley B, et al: The use of carboplatinum and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 47:49-56, 2000
18. Reid R, Asmar L, Khan M, et al: Concurrent carboplatin, paclitaxel (Taxol), and hyperfractionated radiotherapy in unresectable head and neck cancer. Proc Am Soc Clin Oncol 20:203b, 2001 (abstr 2563)
19. Shaw LM, Bonner HS, Schuchter L, et al: Pharmacokinetics of amifostine: Effects of dose and method of administration. Semin Oncol 26:34-36, 1999
20. Koukourakis MI, Kyrias G, Kakolyris S, et al: Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol 18:2226-2233, 2000
21. Anné P, Curran W, Machtay M, et al: A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer (WR-B060). Int J Radiat Oncol Biol Phys 51:84, 2001 (abstr 150)